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Abstract
Aneuploidy, the hold of an abnormal number of chromosomes that differs from
the normal karyotype, is a recognized leading cause of miscarriage and congenital
disabilities. In human gametes and embryos, aneuploidy rates are prevalent, and
these rates increase with advanced maternal age; additionally, it has been suggested
that hormonal stimulation for achieving in vitro fertilization (IVF) protocols further
increases aneuploidy rates. Although about 65% of chromosomally abnormal
embryos culminate in spontaneous miscarriages, there is still evidence of live births
harboring crucial aneuploidies. Furthermore, although some frequent aneuploidies
are consistent, others differ between countries, making it harder to focus on a
specific set of anomalies but vital to focus regionally on those more prevalent.
Preimplantation genetic testing (PGT) is a highly endorsed technique in assisted
reproductive treatments to evaluate possible embryo aneuploidies, genetic defects,
and congenital disorders. On this subject, this study shows that IVF aneuploidy
rates in embryo cohorts of high morphological quality are inversely associated with
implantation rates. In its entirety, this study reinforces the utility of PGT for
embryo evaluation.
Keywords: aneuploidy, preimplantation genetic testing, embryo implantation,
in vitro fertilization, karyotype
1. Introduction
Aneuploidy is defined as a chromosome number that is not an exact multiple of
the usually haploid number [1]. The terms haploid and diploid that describe single
(n) and double (2n) chromosome sets in cells originate from the Greek terms
haplóos meaning single and diplóos meaning double. The term ploidy was subse-
quently derived to describe the total chromosome content of cells. Consequently,
the term euploid refers to a chromosome with an exact multiple of the haploid
number [2]. Human body cells (somatic cells) are diploid, carrying two complete
sets of chromosomes: one set of 23 chromosomes from their father and one set of 23
chromosomes from their mother; the two sets combined provide a full complement
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of 46 chromosomes. Human gametes (or sex cells), sperm and oocytes, are haploid
and contain only one set of 23 chromosomes.
Aneuploidies can occur either by chromosome gains (trisomies) and losses
(monosomies) due to chromosome segregation errors, the so-called “whole chro-
mosomal” aneuploidy or due to rearrangements of chromosomal parts, often
accompanied by deletions, amplifications, or translocations of large regions of the
genome that is referred to as a “structural” or “segmental” aneuploidy [3]. Whole
chromosomal aneuploidies might arise due to random and sporadic chromosome
missegregation events that occur with low frequency during any cell division. The
missegregation levels range from 1/1000 to 1/10,000 in human cells [4].
Meiosis generates haploid gametes through a specialized cell division process
that consists of one round of DNA replication followed by two cell divisions. The
first division, or meiosis I (MI), involves the segregation of homologous chromo-
somes from each other, whereas meiosis II (MII) involves the segregation of the
sister chromatids. Missegregation can also occur in germline cells, and the errors
that arise in meiosis result in aneuploid embryos [5]. This chapter aims to provide
evidence that supports the use of PGT for embryo evaluation and euploid embryo
selection due to a positive correlation with fertilization rates.
2. Incidence of aneuploidy
Errors in meiotic chromosome segregation frequently occur during oogenesis
(20%), especially during the first meiotic division; this incidence of meiotic errors
in oocytes is more elevated in women with advanced maternal age and may be due
to the prolonged time that oocytes spend arrested at meiosis I stage, before ovula-
tion [6]. However, some patterns of nondisjunction appear to be chromosome-
specific; almost all cases of trisomy 16 are linked to errors at maternal MI, while MII
errors are surprisingly common in trisomy 18. Oppositely, in sperm the incidence of
aneuploidy is only 2%. Another considerable percentage of errors (20%) arise
during the first mitosis after fertilization. Among clinically recognized spontaneous
abortions (fetal deaths occurring between 6 and 8 weeks and 20 weeks gestation),
the incidence increases to 50% [7]; the most common specific abnormalities are
sex-chromosome monosomy (45,X), accounting for nearly 10% of all spontaneous
abortions, and trisomies 16, 21, and 22, which together constitute 50% of all triso-
mies identified in spontaneous abortions. The incidence among stillbirths (fetal
Chr Case report References
1 Pure duplication 1q41-qter: further delineation of trisomy 1q syndromes
Partial duplication 1q: reports of five cases and review of the literature
[9]
[10, 11]
2 Duplication 2q2.1-q3.1
Partial trisomy 2q: two cases
[12, 13];
[14]
3 Duplication 3p syndrome: reports of three cases and review of the literature [15–17]
4 Patient with trisomy 4p
Partial duplication and duplication region 4q28.3-qter in monozygotic twins with
discordant phenotypes
[18]
[19, 20]
5 Trisomy 5p: reports of four cases report and review of the literature [21–23]
6 De novo “pure” partial trisomy (6)(p22.3!pter): case report/review
Familial trisomy 6p in mother and daughter
[24]
[25]
7 Interstitial de novo tandem duplication of 7 (q31.1-q35)
New case of pure partial 7q duplication
[26]
[27]
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deaths occurring between 20 weeks gestation and term) is 4% with the types of
abnormality being similar to those identified in newborns, and 0.3% of live-born
are aneuploid with the most common abnormalities being trisomies 21, 18, and 13
and sex-chromosome trisomies 47,XXX, 47,XXY, and 47,XYY [5, 8].
2.1 Aneuploidies and live births
Although about 65% of chromosomally abnormal embryos culminate in sponta-
neous miscarriages, there is still evidence of live births harboring crucial aneu-
ploidies. Table 1 describes cases that are well documented.
3. Impact of aneuploidy on the efficiency of ART
Assisted reproduction is a solution in many of the growing cases of infertile
couples worldwide. A high rate of embryos produced in vitro presents chromosomal
aneuploidy (50%), and such aneuploid embryos have reduced the potential for
achieving a viable pregnancy. Such abnormalities are recognized as the leading
cause of implantation failure and spontaneous miscarriage [60]. Among concep-
tions that survive to term, aneuploidy is the leading genetic cause of developmental
Chr Case report References
8 Trisomy 8: report of four cases [28]
9 Pure 9p trisomy derived from a terminal balanced unreciprocal translocation
Trisomy 9: review and report of two new cases
[29]
[30]
10 Distal 10q trisomy with copy number gain in chromosome region 10q23.1–10q25.1
Proximal 10q duplication in a child with severe central hypotonia
[31]
[32]
11 Partial 11q trisomy syndrome: two cases [33, 34]
12 Clinical report of a patient with de novo trisomy 12q23.1q24.33 [35]
13 Trisomy 13, Patau’s syndrome: reports of three cases [36–38]
14 Partial proximal trisomy 14 [39]
15 Duplication of distal 15q: reports of 14 cases [40, 41]
16 Partial trisomy/long arm of chromosome 16: case report/review of literature
Complete trisomy 16: a case report
[42]
[43]
17 A 790 kb chromosome 17p13.3 microduplication: case report/literature review [44, 45]
18 Trisomy 18, Edward’s syndrome: reports of five cases and discussion [46–48]
19 Three cases of trisomy 19 [49, 50]
20 20q11.2 duplication syndrome and pure trisomy 20p [51, 52]
21 Cardiovascular and general health status of adults with trisomy 21 [53]
22 Trisomy 22 syndrome: a report of four cases in newborns and literature review [54–56]
X Fragile X syndrome: a case report/review of clinical and molecular diagnoses [57, 58]
Y Morphology and pathogenesis of 47,XYY/47,XY patients super male syndrome [59]
Chr, chromosome number.
Table 1.
Case reports of live births with complete or partial chromosomal abnormalities (mosaic or multiple aberrations
are not considered).
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disabilities and mental retardation [5]. Table 2 describes data from different infer-
tility centers predominantly showing that aneuploidy rates are similar.
The relatively high aneuploidy rate observed in human embryos after an IVF/
ICSI cycle has been attributed to the technique itself since this prevalence seems to
be lower in natural conceptions [61]. Many hypotheses have been proposed that
may explain these findings: (1) controlled ovarian stimulation treatments, (2) fac-
tors related to the ICSI technique and (3) lab conditions as embryo culture.
3.1 Ovarian stimulation and the incidence of embryo aneuploidy
To increase the number of oocytes that can be retrieved for IVF, gonadotrophins
are commonly used for superovulation in humans. Exogenous administration of
gonadotrophins results in higher concentrations of steroids that may affect oocyte
and embryo quality. Ovarian stimulation effects have been well characterized
mainly in the murine model and have shown that aggressive stimulation leads to a
poorer embryo development potential that could increase the chromosomal abnor-
mality rate [79]. In humans, studies are scarce and less conclusive. A recent study in
a population of young normovulatory women showed that a high ovarian response
after controlled ovarian stimulation with moderate gonadotropin doses did not
increase the embryo aneuploidy rate. Indeed, the higher the ovarian response, the
more the euploid embryos obtained [80]; the remaining question is whether this
can also be extrapolated to infertile patients with good ovarian reserve.
3.2 Intracytoplasmic sperm injection (ICSI) technique and the incidence of
embryo aneuploidy
ICSI has become critical for the treatment of severe male infertility. The princi-
pal feature of ICSI is the direct injection of spermatozoa into an oocyte, which
facilitates the production of fertilized embryos regardless of semen characteristics,
such as sperm concentration and motility. However, the chromosomal integrity of
ICSI zygotes is degraded compared to zygotes obtained from an in vitro fertilization
[81, 82]. During the ICSI procedure, a sperm pretreatment is performed to mimic
the conditions of natural fertilization and support the progression of fertilization
effects. Studies on mouse models revealed that the chromosomal integrity of
zygotes derived from ICSI without any pretreatment of spermatozoa was impaired
in comparison with zygotes derived from conventional IVF [83]; even the culture
sperm conditions may affect the chromosomal stability of the embryo [84]. Chro-
mosomal damage may occur due to the injection of non-capacitated, acrosome-
intact spermatozoa, so to reduce the risk of chromosomal aberrations during the
ICSI procedure, it is crucial that sperm capacitation and the acrosome reaction be
appropriately artificially induced in the proper medium before use [85].
3.3 Embryo culture and the incidence of embryo aneuploidy
Fertilization and embryo development in vitro have the potential to introduce
(often inadvertently) stress which cannot only impair embryo development in the
laboratory but also have downstream effects after transfer.
In vivo, the developing preimplantation embryo is exposed to gradients of
nutrients, hormones, cytokines, and growth factors as it progresses through the
fallopian tube to the uterus. Within the lumen of the female tract, the embryo
resides in a few 100 nanoliters of a complex viscous fluid characterized by high
levels of mucins, albumin, and glycosaminoglycans and by reduced levels of oxygen
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Nsamples
(country)
Day
of
biopsy
Aneuploidy
rate
Trisomy
%
Monosomy
%
Most affected
chromosomes
Less affected
chromosomes
Ref.
87 (India) 3 54 14.9* 42.5* 22, 18 No data [62]
150
(Japan)
5 40.6 18* 21.3* 15, 22, 21, 16, 18 4, 12 [63]
52 (UK) 5 40.4 51.3# 48.7# 22, 16, 15, 18,
21, X
1, 2, 5, 10, 17,
19
[64]
12 (UK) 3 75 22* 11* 20, 21, 22 6 [65]
5879
(USA)
3 70.6 No data No data No data No data [66]
5 47.8
759 (UK) 3 64.6 40# 60# 16, 22, 21, 4, 5 4, 6 [67]
274 (US) 3 72.3 39.8* 44.5* 22, 16, 7 6, 9, 19 [68]
192 (Italy) 5 55.2 37.9* 42.7* No data No data [69]
240
(Mexico,
Center A)
5 36.3 5.34* 5* 16, 22, XXX, 9 3, 7, 8, 10, 12,
18, 20
[70]
6 61.1 5.55* 10*
210
(Mexico,
Center B)
5 48.9 15.96* 4* 15, 16, 21, 4 1, 2, 3, 5, 8, 9,
10, 11, 12, 14,
17, 20, 22, X, Y
6 43.1 14.65* 5*
404
(Mexico)
No
data
60.89 No data No data 4, 15, 22, 16 No data [71]
15,169
(USA)
No
data
No data No data No data 13, 15, 16, 18,
19, 21, 22
1, 12, 3 [72]
2204
(UK)
0 74 56# 44# 16, 21, 22, 15, 19 No data [73]
3 83 49# 51# 22, 16, 19, 21, 13
5 58 47# 53# 22, 16, 15, 21, 19
21 sets
(Italy)
0/1 97.4 Chromosomal loss three
times more frequent
than gain
22, 15, 16, 17 No data [74]
3 47.6+
5 or 6 80++
195 (USA) 0/1 65.5 39.86# 60.14# 22, 13, 15, 16,
19, 21
6, 5, Y, 3 [75]
5/6 45.2 52# 48# 22, X, 16, 18, 21
1025
(Mexico)
3/5 43.9 59.3# 40.7# 16, 21, 22, 19,
15, 20
8, 4, 3, 2, 7, 1 Current
study
*Percentage of the total number of samples.
#Percentage of the total number of aneuploid samples.
+Rate from the previous stage of development, PBs to blastomere.
++Rate from the previous stage of development blastomere to TE, PBs = polar bodies,TE = trophectoderm.
For the current study, infertile patients who underwent ART at the Ingenes Institute were included. The
patients were clinically evaluated according to a standardized protocol that includes family and personal clinical
history. The protocol was approved by the Ethics Committee of the Ingenes Institute, and a signed informed
consent was obtained from all patients. IVF, embryo biopsy, and mCGH were performed according to the
standard protocols of the Institute Ingenes as previously described [76, 77]. Only optimal morphological embryos
were considered for this study. Selection and embryo transfer were done on Day 3 or Day 5 of development
according to the embryo morphological assessment, using the criteria established by the Istanbul consensus
Workshop on Embryo Assessment [78].
Table 2.
Aneuploidy rates of different IVF clinics around the world; when mentioned, the most commonly affected
chromosomes are listed.
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(typically 2–8%). The embryo is in constant motion, moved by gentle ciliated and
muscular action of the female tract [86]. This scenario is in stark contrast to the
laboratory environment, where typical gametes and embryos are exposed to rela-
tively large volumes of culture medium, remain static during culture while resting
on a polystyrene substrate, and create unstirred layers where the end products of
metabolism concentrate and nutrients become limited [87].
Embryos are sensitive to both chemical and physical signals within their microen-
vironment. Factors within the laboratory as oxygen level, ammonium released from
amino acids into the culture, poor laboratory air quality, temperature and pH, oil
overlay, embryo culture volume/density, the static nature of culture, light, or even
mechanical factors as pipetting, can negatively impact gametes and embryos and
generate stress. When more than one stress factor is present in the laboratory, more
negative synergies can result, and these factors play a significant role in influencing
the development and events post transfer [88]. For example, recent studies have
reported that a decrease in temperature has the potential to affect the stability of the
oocyte’s meiotic spindle, reducing fertilization rates, delaying embryo development,
and decreasing clinical pregnancy rates [89]. However, more studies are needed to
demonstrate the impact of embryo culture on aneuploidy rates.
4. Aneuploidy detection: techniques for PGT
PGT is the genetic diagnosis analysis performed to identify euploid embryos
before uterine transfer [90]. PGT determines the numeric chromosomal constitu-
tion of a cellular biopsy sample obtained from a cultured embryo to determine its
competence [91, 92].
PGT was first described in 1990 by Handyside et al. [93] when the sex of the six-
to eight-cell stage embryos from two couples with a known risk of transmitting X-
linked diseases was assessed by DNA amplification of a Y chromosome-specific
repeat sequence. The earliest PGT studies in the 2000s were based on the fluores-
cence in situ hybridization (FISH) technique where 3–12 chromosomes can be
analyzed on the cleavage stage or polar body biopsies [90]. Those studies had
disappointing results in clinical practice since it had no beneficial effect on live birth
rate after IVF [94]. The major drawback of FISH-based PGT is the limited number
of chromosomes that can be analyzed considering that aneuploidy can affect any of
the 22 autosomes and both sex chromosomes [95]; consequently, there have been
dramatic improvements in PGT technology to make it valuable for clinical practice.
Nowadays, several methodologies for 24-chromosome analysis are available for
clinical use that aim to increase implantation rates and decrease miscarriage rates
associated with IVF [90]: microarray comparative genomic hybridization (mCGH),
single-nucleotide polymorphism (SNP) microarray, real-time polymerase chain
reaction (qPCR), and next-generation sequencing (NGS) [96, 97]. This review will
focus on the relevant aspects of the PGT techniques used in our laboratory.
4.1 Microarray comparative genomic hybridization (mCGH)
mCGH is a ratio labeling protocol to compare the DNA product of a clinical
sample to a healthy control. For PGT, biopsied embryonic cells must be lysed to
extract the sample’s DNA, which will be further amplified by a protocol that
provides whole genome coverage [90, 95, 98]. The resulting DNA products are
co-hybridized with a standard DNA control sample (46,XY and 46,XX) with a
series of site-specific fluorophores on a microarray chip with approximately 4000
markers spaced throughout the genome [90]. Then, a confocal laser platform
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detects the relative color intensity, and a bioinformatics compares the intensity of
each fluorophore in the sample versus the control to identify any bias and deter-
mine the ploidy status of the sample [90, 95, 98].
The mCGH analysis reports the ratio of sample DNA to a reference DNA, as a
chromosomic profile where the molecular karyotype is represented. Usually, the
sample DNA is labeled with a green fluorescent dye, while the reference DNA
sample is tagged red [99]. Thus, diploid embryos will have a relatively equal ratio of
green-to-red fluorescence in every pair of chromosomes, represented as a continu-
ous horizontal plot line. Monosomy will be represented as a clear downward devia-
tion in the plotted line, indicating a relative lack of green-to-red signal intensity; in
contrary, a trisomy will be displayed as an upward deviation in the plotted line due
to a relative increase in the green-to-red signal intensity.
The specificity rate of mCGH-based PGT is about 99% [90]. The test results can
be available within 12–15 h, considering that the entire analysis can be performed
during this short time frame [90, 91]. Additionally, brand-specific features are
offered by each manufacturer: Agilent’s GenetiSure Pre-Screen Microarray offers a
detection rate of 100% for aberrations >10 Mb and 89% for >5.3 Mb [100];
KaryoLite BoBs Kit from Perkin Elmer uses an alternative BACs-on-Beads technol-
ogy and results are interpreted by the BoBsoft™ analysis software [99]; and RHS’s
EmbryoCellect Kit is the only mCGH-based PGT validated for mosaicism detection
[101]. Recently, Illumina’s 24sure PGS Microarray had been discontinued, and the
NGS-based VeriSeq PGS is now offered as an alternative solution [102].
mCGH entails some disadvantages: first, the embryo sample requires a previous
whole genome amplification (WGA) process to support single-cell diagnostics by
mCGH [95], raising the possibility of introducing errors during the amplification
[91]; second, mCGH is a semiquantitative technique that only reports the ratio of
sample DNA to a reference DNA; it is to say that only imbalances in DNA content
can be identified. Therefore, mCGH is unable to detect uniparental disomic or
triploid embryos as it cannot discriminate between 46,XX from 69,XXX, and 46,
XY from 69,XXY [90, 91, 95]. Last, the mCGH used for PGS cannot identify
structural chromosome aberrations or diagnose mosaicism in a trophectoderm
sample [90].
4.2 Next-generation sequencing (NGS)
NGS refers to the emerging technology of non-Sanger-based DNA sequencing
that allows the sequence in parallel millions of DNA strands with high-throughput
yield. In the field of ART, this powerful tool is being applied for PGT to replace
cytogenetic microarrays [98, 102].
Different platforms are commercially available for NGS with different techno-
logical approaches. Illumina’s MiSeq NGS platform applies a sequencing-by-
synthesis method, where DNA is attached and amplified in situ to be subsequently
used as a template for synthetic sequencing with fluorescent-labeled reversible-
terminator nucleotides [103]. Ion Torrent NGS technology, commercialized by
ThermoFisher Scientific, is based on collecting data by sensing the hydrogen ions
that are released as by-products when nucleotides are incorporated by a template-
directed DNA polymerase synthesis on an ion chip [104].
Despite the dissimilarities between platforms, the common basis of chromosome
copy number analysis by NGS is the fragmentation of the amplified DNA sample
into small segments of 100–200 base pairs that are further sequenced in parallel
until the number of reads covering a determined position in the genome is attained,
in general, a 30 coverage (sequencing each base pair 30 times) ensures sufficient
accuracy. The sequence data obtained are then compared with a reference genome
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and counted by bioinformatics software. The copy number of a specific chromo-
some should be proportional to the number of counted sequences; therefore, an
increase or reduction in the number of reads will, respectively, represent a trisomy
or monosomy [97, 99].
NGS allows to simultaneously perform both qualitative and quantitative ana-
lyses of multiple embryos with high-resolution data for chromosomal analysis
[96, 97]. The higher sensitivity and precision offered by NGS [96, 105, 106] makes
possible to exclude embryos with mosaicism [105, 106] and partial aneuploidies or
triploidies [106], improving pregnancy outcomes due to its enhanced capability for
detecting those challenging abnormalities.
PGT by NGS can predict not only chromosome copy number for the diagnosis of
whole chromosome aneuploidy with 99.98% assignment consistency [97] but also
single-gene disorders [107], abnormalities of the mitochondrial genome [108], and
segmental chromosome imbalances [97, 99]. Balanced chromosomal
rearrangements cannot be detected by NGS [97].
The increasing demand and accelerated development are continuously reducing
the cost of NGS technology [109]. Also, potential cost-benefit ratios can be achieved
when the full sequencing capacity of the apparatus is exploited [96, 97, 99].
Furthermore, molecular tools, like barcoding, are being implemented to allow
multiplex high-throughput sequencing [110]; this promising strategy will reduce
the diagnosis’ cost per patient by performing simultaneous analysis of multiple
embryos from different patients [97].
5. Aneuploidy and women age
In our study, by analyzing the mCGH data, the total number of aneuploidies
was found to be 734, and from these, 641 (87.3%) were derived from patients
and 93 (12.7%) from donors. Overall, this study displayed similar rates of
monosomies, trisomies, double aneuploidies, and multiple aneuploidies. The
total number of monosomies (191) was similar to the number of trisomies (194),
accounting for 26 and 26.4% of the total aneuploidies, correspondingly.
Furthermore, the total number of double (165) and multiple (184) aneuploidies
was also very similar, accounting for 22.5 and 25.1% of the total aneuploidies,
correspondingly. Nevertheless, it is worth noticing that when considering only the
donor group, monosomies seem to be more prevalent: 38.7% of the total donors’
aneuploidies were monosomies vs. 24.7% of trisomies, 16.1% of double aneu-
ploidies, and 20.4% of multiple aneuploidies; what is more, the percentage of
monosomies in the donor group is higher than that of the monosomies of the patient
group (38.7 vs. 24.3%). The most common monosomies affected chromosomes 15,
16, and 22, whereas the most common trisomy affected chromosomes 16, 19, and 21
(Table 3).
It has been shown that the lowest risk for embryonic aneuploidy is between ages
26 and 30, with aneuploidy rates steadily increasing with maternal age after
26 years of age [111] and leaping significantly from the age of 39 [112]. For this
reason, women of advanced maternal age are encouraged to favor oocyte donation
to yield high-quality viable embryos.
Interestingly, some studies have identified that women of younger ages possess
an increased prevalence of aneuploidy, with >40% of aneuploidy in women of
23 years and under [111] and 58% of aneuploidy in women of <31 years of age. In
the current study, both the donor (≤29 years) and the patient group of ≤29 years
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displayed high aneuploid rates, 28.5 and 27.4%, respectively (Table 4). Given the
high rates of aneuploidy in younger women, attention should be paid in detecting
aneuploidy in embryos from women of young maternal age, especially since this
group of patients is not routinely encouraged to perform a PGT. Still, whether there
is a difference between the distribution of aneuploidies between donors and
patients remains uncertain.
When stratifying our analysis in age groups (a, ≤29; b, 30–34; c, 35–37; d, 38–40;
e, 41–43; and f, ≥44 years of age), a visible continuous increase in aneuploidy rate
can be observed as maternal age increases (Table 4); furthermore, this increase in
aneuploidy goes hand in hand with a continuous decrease in implantation, as it
can be observed in the decrease of positive beta-human chorionic gonadotropin
(β-hCG) values as age increases (β-hCG values ≥10 mUI/ml from Day 14 after
transference were considered positive).
All Patients Donors
Total 734 641 93
Monosomy 191 (26.0%) 155 (24.3%) 36 (38.7%)
Chr 15 13 13 0
Chr 16 21 18 3
Chr 22 22 22 0
Chr X 10 8 2
Chr Y 40 26 14
Trisomy 194 (26.4%) 171 (26.7%) 23 (24.7%)
+Chr 16 26 24 2
+Chr 18 9 7 2
+Chr 19 23 21 2
+Chr 20 17 13 4
+Chr 21 20 20 0
+Chr 22 19 19 0
+Chr X 10 8 2
+Chr Y 1 1 0
Dual 165 (22.5%) 150 (23.4%) 15 (16.1%)
Multiple 184 (25.1%)a 165 (25.7%)b 19 (20.4%)c
The current study included 441 patients, resulting in 474 cycles. A total of 1629 embryos were analyzed; from those, 54
were excluded due to failed WGA, leaving 1575 embryos for analysis, 1258 from patients, and 317 from donors.
Biopsies were performed at the blastomere (Day 3, patients = 238 and donors = 50) and blastocyst stages (Day 5,
patients = 1020 and donors = 267). Finally, 734 embryos (46.6%) were found to be aneuploid (patients = 641 and
donors = 93). The total number of monosomies and trisomies is provided along with their respective percentages;
furthermore, the number of the most common aneuploidies of the mCGH data is listed.
aNine embryos had completely abnormal mCGH profiles.
bEven embryos had completely abnormal mCGH profiles.
cTwo embryos had completely abnormal mCGH profiles.
Table 3.
Most frequent types of aneuploidies in the mCGH data of the current study.
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Category ≤29
a
30–34
b
35–37
c
38–40
d
41–43
e
≥44
f
Donors
g
Number of samples (n, cycles) 27 66 72 105 90 31 83
Age (years) 27.0  2.4b,c,d,e,f,g 32.5  1.3a,c,d,e,f,g 36.1  0.7a,b,d,e,f,g 39.0  0.8a,b,c,e,f,g 41.8  0.8a,b,c,d,f,g 45.0  1.6a,b,c,d,e,g 22.8  3.0a,b,c,d,e,f
Body mass index (kg/m2) 23.6  3.8g 24.6  3.8g 24.3  3.9g 24.4  3.7g 24.8  3.8g 24.6  2.8g 21.8  2.5a,b,c,d,e,f
Ova collected (n) 16.8  7.9e,f 17.3  9.8d,e,f 16.1  9.0d,e,f 12.0  6.3b,c,g 11.0  5.9a,b,c,g 8.9  6.0a,b,c,g 15.8  8.1d,e,f
Ova fertilized (n) 14.3  6.9e,f 15.2  8.6d,e,f 13.6  7.5d,e,f 10.3  5.2b,c,g 9.8  5.5a,b,c,g 7.6  4.8a,b,c,g 13.9  6.2d,e,f
Embryos (n) 11.2  6.3e,f 11.7  7.9d,e,f 10.6  6.0d,e,f 7.7  4.2b,c,g 7.5  4.6a,b,c,g 6.2  3.9a,b,c,g 10.4  4.6d,e,f
Fertilization rate (%) 77.9  17.0 76.3  15.1 79.7  14.2 76.6  16.6 77.0  18.9 83.6  15.2 76.1  16.0
Aneuploidy rate (%) 27.4  33.3d,e,f 36.0  29.2d,e,f 35.7  30.3d,e,f 57.7  34.9a,b,c,f,g 66.6  37.7a,b,c,g 87.4  19.5a,b,c,d,g 28.5  28.7d,e,f
Pregnancy rate (%) 60.87b,c,d,e,f,g 50.99a,c,d,e,f,g 49.09a,b,d,e,f,g 44.00a,b,c,e,f,g 55.17a,b,c,d,f,g 42.86a,b,c,d,e,g 50.79a,b,c,d,e,f
Values are shown as mean  standard error. Significance was determined by one-way ANOVA followed by a Bonferroni or Dunnett’s T3 post hoc test. Superscripts indicate a significant difference
(p < 0.05, two-tailed):
aVersus ≤29 years old group.
bVersus 30–34 years old group.
cVersus 35–37 years old group.
dVersus 38-40 years old group.
eVersus 41–43 years old group.
fVersus ≥44 years old group.
gVersus donors.
Table 4.
Comparative of aneuploidy and pregnancy rates between age groups.
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6. Remarks
One of the most critical reasons for unsuccessful IVF procedures is implantation
failure due to aneuploid embryos. Aneuploidies are the primary cause of perinatal
death and genetic abnormalities; consequently, the detection of chromosomal dis-
orders constitutes the most frequent indication for PGT. Here, we report on the
aneuploidy rates found in IVF procedures in Mexico. Even though there are studies
that assert that PGT does not improve pregnancy rates, we show that aneuploidy
rates inversely correlate with implantation and that levels of aneuploidy among
high morphological quality embryos are still an important issue to be faced in
everyday ART practice, and this evidence works in favor of continuing to use PGT
analysis.
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PGS preimplantation genetic screening
PGT preimplantation genetic testing
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